

14 January 2025

Advanced Medical Solutions Group plc
("AMS" or the "Group")

Full Year 2024 Trading Update

~ Enlarged Group performing well and in line with consensus expectations ~

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a world-leading specialist in tissue-healing technologies, today announces a trading update for the twelve months ended 31 December 2024. The Group expects to announce its Full Year results on 19 March 2025.

Following the acquisition of Syntacoll on 1 March 2024 and the transformative acquisition of Peters Surgical on 1 July 2024, excellent progress has been made on integrating both businesses, and the enlarged Group is performing well, with strong growth continuing across all surgical product categories. In response to changing market dynamics, planned strategic initiatives within the Woundcare business are also being successfully executed, which are expected to positively impact margins in 2025.

The Group expects to report Full Year 2024 revenues of approximately £177 million (2023: £126.2 million), EBITDA of £40.0 - £40.5 million (2023: £ 29.7 million) and adjusted Pre-tax profit of £29.2 - 29.7 million (2023: £25.9 million).

Chris Meredith, Chief Executive Officer of AMS, said: "The progress we made in the second half of 2024 has strengthened the confidence we have in the strategic rationale for the recent acquisitions of Peters Surgical and Syntacoll. The synergistic benefits they represent to AMS, in terms of products, expertise, geographic reach and scale, are clearer than ever. As we start the new year as an enlarged and more competitive Group, I remain confident and excited about the growth and opportunities that we expect in 2025 and beyond."

- End -

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc

Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Michael King, Investor Relations

Tel: +44 (0) 1606 545508

ICR Healthcare

Mary-Jane Elliott / Lucy Featherstone

Tel: +44 (0) 20 3709 5700

AMS@icrhealthcare.com

Investec Bank PLC (NOMAD & Broker)

Gary Clarence / David Anderson

Tel: +44 (0) 20 7597 5970

HSBC Bank plc (Broker)

Joe Weaving / Stephanie Cornish

Tel: 44 (0) 20 7991 8888

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made seven acquisitions: Sealantis, an Israeli developer of innovative internal sealants, Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business, Connexion, an Irish tissue adhesives specialist, Syntacoll, a German specialist in collagen-based absorbable surgical implants and Peters Surgical, a global provider of specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate devices.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, Thailand, India, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, France, Poland, Benelux, India, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 1,500 employees. For more information, please see www.admedsol.com.

-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TSTBJMRTMTJBBBA